Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurotech International ( (AU:NTI) ) has shared an announcement.
Neurotech International has secured binding commitments for a $4 million placement from both existing and new investors, with directors also participating. The funds will be used to advance NTI164’s non-clinical toxicology and clinical programs, regulatory submissions, and general working capital, strengthening the company’s position in developing treatments for paediatric neurological disorders.
More about Neurotech International
Neurotech International Limited (ASX: NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164 and has conducted several clinical trials in Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), and Rett Syndrome.
Average Trading Volume: 1,174,640
Technical Sentiment Signal: Sell
Current Market Cap: A$19.42M
For detailed information about NTI stock, go to TipRanks’ Stock Analysis page.